Scholarlink

<p>We identified a subset of patients with colorectal cancer (CRC) enriched with “collagen-TAMs,” designated the CM class, using large integrated colon cancer transcriptome and single-cell transcriptome datasets. This classification system could be used as an extension of the traditional CMS classification system for CRC to guide more accurate classification and treatment.</p><p>We also screened CAF-derived <i>THBS2</i> as a potential biomarker for CM and found that it plays an important role in CRC disease models in vitro and in vivo, promoting tumor development and metastasis as well as TAM recruitment. Targeting <i>THBS2</i> combined with PD-1 therapy effectively improved the therapeutic effect of immunotherapy in vivo. The CM classification provides a new perspective for CRC treatment, and <i>THBS2</i>, which is highly expressed in CM cases, can be used as a new potential combined target for immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of the "Collagen-Macrophage" sub-category of patients with colorectal cancer as an extension of the CMS4 subtype with THBS2 as a therapeutic target

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Shuwen Chen,
  • Zhaoyan Jiang,
  • Wanxuan Song,
  • Chuqiao Lu,
  • Yanbing Lin,
  • Shiyao Xu,
  • Kunxin Xie,
  • Li Wan,
  • Xiaoqin Yuan

摘要

We identified a subset of patients with colorectal cancer (CRC) enriched with “collagen-TAMs,” designated the CM class, using large integrated colon cancer transcriptome and single-cell transcriptome datasets. This classification system could be used as an extension of the traditional CMS classification system for CRC to guide more accurate classification and treatment.

We also screened CAF-derived THBS2 as a potential biomarker for CM and found that it plays an important role in CRC disease models in vitro and in vivo, promoting tumor development and metastasis as well as TAM recruitment. Targeting THBS2 combined with PD-1 therapy effectively improved the therapeutic effect of immunotherapy in vivo. The CM classification provides a new perspective for CRC treatment, and THBS2, which is highly expressed in CM cases, can be used as a new potential combined target for immunotherapy.